Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Janux Therapeutics, Inc. (JANX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$18.18+2.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for JANX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in cash from operating activities | Cash flow improved from -$28.54M to -$12.34M in one quarter. | Improving | Cash flow worsens beyond -$12.34M in next 4 quarters | Cash from operations: $12.484M FY2026-Q2; GAAP. Published target: Cash from operations improves to better than -$12.34M. Target period is not explicitly aligned with this observation. Aug 6, 202612,484,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
JANX is a speculative clinical-stage biotechnology company, meaning its business case depends on developing treatments that are still being tested. Its long-term thesis is in a watch state: management is advancing the pipeline, while recent financial performance is below its industry cohort and the company remains loss-making.
The valuation model shows JANX at a 4.78 premium versus peers, with optionality, or potential value from future pipeline success, driving the gap. The expectations gap is 0.36, but model confidence is low, so the degree of optimism already reflected in valuation is uncertain.
Near term, continued clinical enrollment and planned initiation of JANX013 support pipeline progress, while stable cash near $970 million provides funding for development. Research and development spending rose modestly in the latest quarter, and a recent earnings miss plus a high-miss-rate industry make the next results worth watching.
Over the multi-year view, the central swing factor is whether clinical programs advance while management maintains enough cash to support them. Near term, weakening jobs data could increase recession concerns, while results and guidance from healthcare peers could either reinforce or weaken the sector tailwind.
JANX’s long-term thesis has support from pipeline progress, cash resources, and a stronger sector backdrop, but it remains a loss-making, elevated-risk story with uncertain valuation expectations. The next read depends on clinical execution, cash discipline, and incoming company and sector results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Janux Therapeutics, Inc.'s published investment case. The stated target is Earnings loss narrows from -$1.76 FY26 toward break-even. |
| Under Pressure |
| EPS loss worsens beyond -$1.76 in FY26 |
Diluted EPS: $-0.35 per share FY2026-Q2; GAAP. Published target: Earnings loss narrows from -$1.76 FY26 toward break-even. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-0.35 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress in developing and commercializing therapy with Bristol-Myers Squibb | Janux works with Bristol-Myers Squibb on a new cancer therapy. | Intact | Partnership progress stalls or ends before FY26 | Qualitative: BMS partnership active (Jan 2026) Jan 2026 BMS collaboration agreement signed; no news of partnership termination or stall. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.70 → $-2.67 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-07-25 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-07-26 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-07-27 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-07-28 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-07-29 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-07-30 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-07-31 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-08-01 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-02 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-08-03 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-08-04 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-08-05 | $-2.70 | $6,952,140 | 13 / 14 |
| 2026-08-06 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-07 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-08 | $-2.70 | $7,486,920 | 13 / 13 |
| 2026-08-09 | $-2.70 | $7,486,920 | 13 / 13 |
| 2026-08-10 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-12 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-13 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-14 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-15 | $-2.68 | $6,978,571 | 12 / 9 |
| 2026-08-16 | $-2.68 | $6,978,571 | 12 / 9 |
| 2026-08-17 | $-2.68 | $6,978,571 | 12 / 9 |
| 2026-08-18 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-19 | $-2.68 | $6,978,571 | 12 / 10 |
| 2026-08-20 | $-2.67 | $8,716,538 | 11 / 10 |
| 2026-08-21 | $-2.67 | $8,716,538 | 11 / 10 |
| 2026-08-22 | $-2.67 | $8,716,538 | 11 / 10 |
| 2026-08-23 | $-2.67 | $8,716,538 | 11 / 10 |
| 2026-08-24 | $-2.67 | $8,716,538 | 11 / 10 |
| 2026-08-25 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-26 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-27 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-28 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-29 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-30 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-08-31 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-01 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-02 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-03 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-04 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-05 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-06 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-07 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-08 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-09 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-10 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-11 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-12 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-13 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-14 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-15 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-16 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-17 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-18 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-19 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-20 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-21 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-22 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-23 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-24 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-25 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-26 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-27 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-28 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-29 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-09-30 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-01 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-02 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-03 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-04 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-05 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-06 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-07 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-08 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-09 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-10 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-11 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-12 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-13 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-14 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-15 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-16 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-17 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-18 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-19 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-20 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-21 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-22 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-23 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-24 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-25 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-26 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-27 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-28 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-29 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-30 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-10-31 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-11-01 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-11-02 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-11-03 | $-2.67 | $8,716,538 | 12 / 10 |
| 2026-11-04 | $-2.67 | $8,716,538 | 12 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 16 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.